NEWS & PRESS RELEASES:

January 12-14, 2025: PharmaNest attends the 2025 JP Morgan Healthcare Conference to develop strategic relationships in the Drug Development and Investors communities.

January, 11 2025: PharmaNest to present at the 2025 MASH-Tag Conference (Deer Park, UT, USA): Along side with Dr. Andy Beck (PathAI), Dr. Dean Tai (Histoindex), Prs. Mary Rinella, Vlad Ratziu and Naim Alkhouri, Dr. Mathieu Petitjean presents PharmaNest’s contributions to “Recent Progress in Measuring Antifibrotic Effects: Data from MASH Clinical Trials” (Presentation here)

December 8, 2024: PharmaNest to present “Contributions of Digital Pathology and Artificial Intelligence to the quantification of histological fibrosis in several organs and biological systems” at the 2024 Keystone Symposium on Fibrosis: Inflammation, Drivers, and Therapeutic Resolution (Abstract here)

November 15, 2024: PharmaNest to present four digital Pathology and AI abstracts at the 2024 Liver Meeting - AASLD 2024 in San Diego (see abstract on our Publications Page)

September 25, 2024: Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology: continuous histological fibrosis scores generated in antifibrotic trials by digital pathology images analysis (DIA) quantify antifibrotic effects with greater sensitivity and larger dynamic range than Conventional Pathology (Press release here)

June 3, 2024: PharmaNest to Present Seven Digital Pathology and AI Communications and Abstracts at the International Liver Congress – EASL 2024, Including Analytical and Clinical Validation Data of Its Digital Biomarker for Fibrosis in Metabolic Associated Steatohepatitis (MASH) (Press Release Here)

May 14, 2024: Dr. Mathieu Petitjean presents PharmaNest and its FibroNest digital Pathology biomarkers and the 2024 BioNJ Partnership Conference.

March 3, 2024: PharmaNest presents four Digtial Pathology and AI communications at the 2024 Keystone Symposium “MASH and Fibrosis: From Molecular Phenotypes to Precision Therapeutics”.

January 10, 2024: PharmaNest attends the 2024 JP Morgan Healthcare Conference satellite events to develop strategic relationships in the Drug Development and Investors communities.

January 6, 2024: Alongside with PathAi and Histoindex, Dr. Mathieu Petitjean presents "FibroNest: single-fiber, Single-cell high content an high resolution digital pathology for the assessment of Liver Biopsies in NASH studies" at the 2024 NASH-TAG conference in Deer Park, UT, USA

November 8, 2023: Alimentiv, AcelaBio, and PharmaNest Unite To Revolutionize Precision Medicine and AI Digital Pathology For NASH/MASH Clinical Trials. (Press Release Here)

November 1, 2023: Dr. Mathieu Petitjean presents PharmaNest and its FibroNest digtal Pathology biomarkers and the 2023 BioNJ’s AI / Digital Health Day

October 13 2023: PharmaNest submits its Digital Pathology biomarker to the Drug Development Program / Biomarker Qualification program at FDA/ CDER (LOI here)

September 20, 2023: Dr. Mathieu Petitjean presents "FibroNest: single-fiber, Single-cell high content an high resolution digital pathology for the assessment of Liver Biopsies in NASH studies" at the Liver Meeting Forum / Paris NASH meeting in Paris, France

September 2, 2023: Dr. Mathieu Petitjean presents "High Resolution and single-fiber Digital Pathology and AI, from Liver Organoids to HCC and outcomes" at the 2023 ESBRA Conference in Graz, Austria

June 22, 2023: PharmaNest Launches Its Digital Pathology Spatially Resolved, Quantitative Tissue Panels to Quantify Tissue Injury and Inflammation in the Context of Fibrotic Conditions (Press Release Here)

June 19, 2023: PharmaNest to present six digital Pathology and AI abstracts at the International Liver Congress -EASL 2023, including liver related clinical outcomes prediction results in NASH (Press Release Here)

March 19, 2023: PharmaNest presents five abstracts to the Keystone Symposium on Fibrosis Pathogenesis and Resolution: From Mechanisms to Therapies (list here).

January 4, 2023, From the Icahn School of Medicine at Mount Sinai: Potential New Targets Identified in Advanced Non-Alcoholic Fatty Liver Disease (Press Release here, published on line in Science Translational Medicine, weblink here)

November 3, 2022: PharmaNest Presents NASH Digital Pathology and AI Results With a Performance That Compares to Histological Stages and Imaging (Press Release here)

September 7, 2022: The QUID-NASH Research Consortium (Paris, France) and PharmaNest, Inc. (Princeton, USA) Enter a Strategic Partnership for the Study of NASH (Press Release here)

June 20, 2022: PharmaNest to Present Eight Digital Pathology and AI Abstracts at the International Liver Congress 2022 (see press release here)

April 28, 2021, From GALMED Pharmaceuticals Ltd, Using FibroNest: Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment (see press release here)

November 12, 2021: PharmaNest Announces New Pre-Clinical and Clinical NASH Data to Be Presented at the AASLD - The Liver Meeting Digital Experience™ (TLMdX) 2021 (see press release here)

August 25,2021, From LIPOCINE Inc, Using FibroNest: Lipocine's LPCN 1144 Met Non-Alcoholic Steatohepatitis ("NASH") Resolution Regulatory Endpoint in Phase 2 LiFT Study (see press release)

April 1, 2021: “New in vitro assay developed to test potential NASH drugs: An assay that combines 3D disease models and automated AI-based fibrosis quantification could accelerate NASH drug discovery”, by Victoria Rees in Drug Target Review ( Article here)

March 29, 2021: Novel Phenomics NASH In Vitro Assay Presented by InSphero AG and PharmaNest Inc at 2021 Society of Toxicology Meeting (see press release here) (see presentation here)

November 11, 2020: PharmaNest Announces New Pre-Clinical NASH and Clinical Liver Cancer Data to Be Presented at the AASLD | the Liver Meeting Digital Experience (TLMdX) 2020 (see press release here)

August 24, 2020: PharmaNest Announces New Pre-Clinical and Clinical NASH Data to Be Presented at the EASL | Digital International Liver Congress 2020 (see press release here)

February 6, 2020: PharmaNest Announces Kidney and Lung fibrosis quantification Data to be Presented at the 2020 Fibrosis and Tissue Repair Keystone Symposium (see press release here)

October 30, 2019: PharmaNest Announces New Adult and Pediatric NASH Data to be Presented at the AASLD – Liver Meeting® 2019 (see press release here)

Sept 24, 2019: PharmaNest Launches FibroNest, the First Multivendor Image Analysis and Translational Platform for the Assessment of the Severity and Progression of Fibrosis in NASH (see press release here)

Deck

Offices:

100 Overlook Center, FL2, Princeton, NJ 08540

FibroNest Operations:

We deliver FibroNest worldwide via the Cloud.